,.
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE • DE LA SANTE
REGIONAL OFFICE FOR THE WESTERN PACIFIC BUREAU RiGIONALDU PACIFIOUE OCCIDENTAL
REGIONAL COMMITTEE Thirtieth session Singapore 2-8 October 1979 Provisional agenda item 11
WPR/RC30/9 30 July 1979 ORIGINAL: ENGLISH
SPECIAL PROGRAMME FOR RESEARCH AND TRAINING IN TROPICAL DISEASES: JOINT COORDINATING BOARD: SELECTION OF GOVERNMENT REPRESENTATIVES A copy of the Memorandum of Understanding on the Administrative and Technical Structures of the Special Programme for Research and Training in Tropical Diseases is attached. It provides for the establishment of a Joint Coordinating Board (JCB) to coordinate the interests and responsibilities of all parties cooperating in the Special Programme. The composition of the JCB is described in Section 2.2 of the attached Memorandum of Understanding. Each Regional Committee of the World Health Organization is responsible for selecting two government representatives to serve on the JCB (see Section 2.2.2 of the attached Memorandum of understanding). At its twenty-ninth session, the Regional Committee selected as the two Member States of the WHO Western Pacific Region whose representatives were to be members of the Joint Coordinating Board, the Philippines, for a period of two years up to 31 December 1979 and Malaysia, fora period of three years up to 31 December 1980, both commencing on 1 January 1978. 1 The initial duration of tenure was different for each country to allow for continuity. At the thirtieth session, the Regional Committee must either decide to extend the membership of the representative of the Government of the Philippines for three years from 1 January 1980, that is until 31 December 1982, or select another Member State to appoint a representative. The Committee's attention is also drawn to the last paragraph of Section 2.2 of the Memorandum of Understanding which indicates that governments and organizations who are Cooperating Parties in the Special Programme (see Section 1.2 of the Memorandum of Understanding) and who have not been selected for membership of the JCB, may attend me~_~ingsu~~_ the JCB as observers subject to its prior, approval. The Regional Director will be happy to communicate the name of any such government or organization to the JCB. It should be noted however that requests for observer status must reach the Standing Committee at least 60 days before the next scheduled meeting of the JCB, which is on 12 and 13 December 1979.
lSee resolution WPR/RC29.Rll, Report of the WHO Regional Committee for the Western Pacific, twenty-ninth session, 1978, page 27.
WPR/RC30/9
,..
page 3
,MSMORANDUM OF UNDERSTANDING ON THE ADMINISTRATIVE' AND TECHNICAL STRUCTURES OF THE: SPECIAL PROGRAMME '. FOR RESEARCH AND TRAINING IN TROPICAL DISEASES
This Memorandum of Understanding describes the functions, composition and operation of the .Joint Coordinating Board, the Standing Committee and the Scientific and Technical Advisory Committee of the Special Programme for Research and Training in Tropical Diseases (hereinafter call~d the. Special Programme). The Special Programme is structured on the basis of co~sponsorship by the United Nations Development Programme (hereinafter called UNDP), and the World Bank (hereinafter called the Bank) and the World Uealth Organization (hereinafter called WHO), and operates within a broad framework of intergovernmental/inter-agency cooperation and participation. The governments apd organizations which met in Geneva on 1 and 2 February 1978 and whose names are listed in Annex 1 hereto, have endorsed the Administrative and Technical Structures of the Special Programme as set forth belOW. A 'summary of the scientific and technical basiS of the Special Programme is attached as Annex 2 hereto.
1.
DEFINITIONS
1.1 The Special Programme is a global programme of international technical cooperation initiated by WHO and co-sponsored by UNDP and the Bank, with the two interdependent objectives of developing improved tools for the control of tropical diseases and strengthening the research capability of affected countries themselves. 1.2 Cooperating Parties are: 1. 2.1
those governments contributing to Special Programme Resources; those governments providing technical and/or scientific support to the SpeCial Programme; and those governments whose countries are directly affected by the diseases dealt with by the Special Programme; those intergovernmental and other non-profit making organizations contributing to Special Programme Resources or providing technical and/or scientific support to the Special Programme.
1.2.2
1.3
The Executing Agency is WHO.
1.4 Special Programme Resources are the finanCial resources made available to the Special Programme by governments and organizations, through the Tropical Diseases Research Fund, an international fund administered by the Bank, the WHO Voluntary Fund for Health Promotion and other agency funds.
2. 2.1
THE JOINT COORDINATING BOARD (JCB) Functions
The .rCB shall, for the purpose of coordinating the interests and responsibilities of the parties cooperating in the Special Programme, have the following functions: R 478
WPR/RC30/9 page 4
2.1.1
Review and decide upon the planning and execution of the Special Programme. For this purpose it will keep itself informed of all aspects of the development of the Special Programme, and consider reports and recommendations submitted to it by the Standing Coillmittee, the Executing Agency, and the Scientific and Technical Advisory Committee (STAC). Approve the proposed plan of action and budget for the comi.ng financial period, prepared by the Executing Agency and'reviewed by the Standing Committee. Review the proposals of the Standing Committee and approve arrangements for the financing of the Special Programme in that period. Review proposed longer-term plans of action and their financial implications. Review the annual financial statements submitted by the Executing Agency, as well as the audit report th~reon, submitted by the External Auditor of the Executing Agency. Review periodic reports which evaluate the progress of the Special Programme towards the achievement of its objectives. Endorse the proposals of the Executing Agency and the Standing Committee for STAC membership. Consider such other matters relating to the Special Programme as may be referred to it by any Cooperating Party.
2.1.2
2.1.3 2.1.4 2.1.5
2.1.6 2.1. 7 2.1.8
·2.2
Composition The .TCBshall consist of 30 members from among the Cooperating Parties as follows: 2.2.1
Twelve government representatives selected by .the contributors to the Special Programme Resources. Twelve government representatives selected by the WIIO Regional Committees from among those countries directly affected by the diseases dealt with by the Special Programme, or from among those providing technical or scientific support to the Special Prograrlune. Three members, deSignated by the JCB itself, from among the remaining Cooperating Parties. The three Agencies which comprise the Standing Committee. ma~
2.2.2
2.2.3 2.2.4
-
Members of the JCB shall serve for a period of three years and
be reappointed.
Other Cooperating Parties may, at their request, be represented as observers upon approval by the JCB.
2.3
Operation 2.3.1
The JCB shall meet in annual session, and in extraordinary session if required, and with the agreement of the majority of its members. The JCB shall elect each year from among its members, a Chairman who shall: - convene and preside over meetings of the JCB; and - undertake such additional duties as may be assigned to him by the JCB.
2.3.2
2.3.3
The Executing Agency shall provide the Secretariat and arrange for supporting services and facilities as may be required by the JCB.
.
WPR/RC30/9 page 5 Subject to such other special arrangements as may be decided upon by the .JCB, members of the .TCB shall make their own arrangements to cover the expenses incurred in attending sessions of the .ICB. Observers shall attend meetings of the JCB at their own expense. Other expenses of the .lCB shall be borne by the Speci·al Programme Resources.
2.3.4
3. 3.1
TJiE STANDING COMMITTEE Composition and Functions
The Standing Committee shall be comprised of the co-sponsors, namely the UNDP, the Bank ann WHO. It shall have the following functions: 3.1.1 Review the plan of action and budget for the coming. financial period, as prepared by the Executing Agency, in time for presentation to the JCB not less than forty-five days before the .]CB' s annual session. Make proposals to the JCB for the financing of the Special Programme for the coming financial period. Approve re-allocation of resources between Programme areas and SCientific Working Groups of the Special Programme during a financial period, upon the recommendation of STAC and the Executing Agency, and report su~h reallocations to the JCB. Examine the reports submitted to the Executing Agency by the ScientifiC and Technical Advisory Committee <STAC) and the Executing Agency's COmments; make the necessary observations thereon, and transmit these, with comments as appropriate, to the JCB. Review particular aspects of the Special Programme, including those which may be referred to it by the JCB, and present findings and recommendations in the form of reports tti the JCB. Inform the JCB, as required, regarding Special Programme matters of interest to the JCB.
3.1.2 3.1.3
3.1.4
3.1.5
3.1.6
3.2
Operation 3.2.1 3.2.2 3.2.3 The Standing Committee shall usually meet at least twice a year; once at the time of the JCB meeting, and additionally between seSSions of the JCB. The Executing Agency shall arrange for supporting services and facilities as may be required by the Standing Committee. Members of the Standing Committee shall make their own arrangements to cover the expenses incurred in attending sessions of the Standing Committee.
4. 4. I
THE SCIENTIFIC AND TECHNICAL ADVISORY COMMITTEE (STAC) Functions The STAC shall have the following functions: 4.1.1 Review, from a scientific and technical standpOint, the content, scope and dimenSions of the Special Programme, including the diseases covered and approaches to be adopted. Recommend priorities within the Special Programme, including the establishment and disestablishment of Scientific Working Groups, and all scientific and technical aciivi ties related to the Programme.
4.1.2
wn/aC30/9 page 6
... 4.1.3 Provide the JCB and the Executing Agency with a continuous independent evaluation of the scientific and technical aspects of all activities of the Special Programme.
For these purposes the STAC may propose and present for consideration such technica) documents and recommendations as it may deem appropriate.
\4.2
Composition
The STAC shall be comprised of ,15-18 scientists and other technical personnel who will serve in their personal capac! tie,s to represent the broad range of biomedical and other disciplines required for Special Programme activities. Members of STAC, including the Chairman, will be selected on the basis of scientific or technical competence by the Executing Agency, in consultation with the Standing Committee and with the endorsement of the JCB. 4.2.1 Members of the STAC, including the Chairman, shall be appointed to serve for a period of three years, and will be eligible for further reapPointment. To maintain continuity of membership, the expiration of the initial terms of office of members of STAC will be staggered.
-
.
4.3
Operation 4.3.1 4.3.2
The STAC shall meet at least once each year. The Executing Agency shall provide the Secretariat to STAC including sustained sci.entific, technical and administrative support. Costs of the STAC shall be borne QY the Special Programme Resources. The STAC shall prepare an annual report on the basis of a full review of all technical and scientific aspects of the Special Programme. This report, containing its findings and recommendations, shall be submitted to the Executing Agency and to the Standing Committee. The Executing Agency shall submi tits comments on the. report to the Standing Committee. The Standing Committee shall then transmit the report, including the comments of the Executing Agency, together with its own observations and recommendations, to the JCB, not less than forty-five days before the JCBts annual session. The Chairman of the STAC, or in his absence a member of the STAC deputized to act for him, shall attend all sessions of the JCB.
4.3.3 4.3.4
5.
TilE EXECUTING AGENCY
The Director-General of WHO, after such consultations 'as he may deem appropriate, shall apPOint the Special Programme Coordinator and the Special Programme Director and appoint or assign all other personnel to the Special Programme as specified in .the plans of work. Drawing as required upon the administrative resources of WHO and in cooperation with the co-sponsors of the Special Programme, the Coordinator will be responsible for the overall management of the Special Programme. Under the authority of the Special Programme Coordinator and drawing to the full upon the scientific and technical resources of WHO, the Director of the Special Programme shall be responsible for the overall scientific and technical development and operation of the Special Programme including the plan of action and budget. 6. TRANSITIONAL PROVISION
'"
The Cooperating Parties attending the preliminary meeting of the Special Programme together with the Sponsoring Agencies have, as an interim measure, carried out the functions of the JCB pending its definitive establishment pursuant to paragraph 2,2 hereof. 2 February 1978
WPB./B.C30/9 pa.e 7
Annex 1
LIST OF PARTICIPANTS ARGENTINA Dr Olindo MARTINO, Adviser in Epidemiology and Pathology, Secretllriat of State Public Health Area Office, Buenos Aires ".
AUSTRALIA Dr R. CUMMING, Assistant Director-General, Health, Canberra Ms lI~len Internatio~al
Ifealth Branch, Department of
FREEMAN, Second Secretary, Permanent Mission of Australia to the United Nations Office at Geneva
AUSTRIA Dr Othmar LAURENCIC, Director, Epidemiological Department, Federal Ministry of Health and Environmental Protection, Vienna BELGIUM Madame S. VERVALCKE, Dlrecteur d t Admlnistration, Administration de 1. Coop'ratlon au Developpement, Bruxelles BENIN Capitaine I. BOURAIMA, Ministre de la Sant' publique et des Affaires sociales, Cotonou Professeur B:C. SADELER, D'partement des Etudes scientifiques et teChniques, Section de Medecine, Universite nationale du B'nin, ,Cotonou BRAZIL Dr Paulo DE ALMEIDA MACHADO, Minister of State for Health, Ministry of Health, Brasilia BURMA Dr Aung Than BATU, Director"'General, Medical Research, Ministry of Health, Rangoon CANADA Dr P. LADOUCEUR, Section Head, UN Programmes Division, Canadian International Development Agency (CIDA) , Ottawa Dr W.G.B. CASSELMAN, Senior Medical Adviser, International Health Services, Department of National Health and Welfare, Ottawa Dr W.T. OLIVER, Research Coordinator, Laboratory Centre for Disease Control, Department of National Health' and Welfare, Ottawa Mr C. SIROIS, First Secretary, Permanent Mission of Canada to the United Nations Office and International Organizations at Geneva
Wl'1l./ RC3 0 /9 page 8
DENMARK Dr Inge JESPERSEN, Deputy Commissioner of Heal th. Melllber of DAi'HDA' s Board, Copenhagen Mr Niels J. LASSEN, Deputy Head of,Division. Danish Internationai Development Agency (DANIDA), Copenhagen EGYPT Dr Elmotaz Billah WBARAK, Under Secretary of Health, Minist:ty of Public Health, C.airo FINLAND Miss Anna-Liisa KORHONEN, Secretary of Section, I>epartunt for International Development Cooperation. Ministry for Foreign Affairs, Helsinki Mrs Helena RDOS. Secretary (Social Affairs). Permanent Mission of Finland to the United Nations Office and other International Organizations at Geneva FRANCE
.
Dr R. GAVARINO. M~ecin en Chef des Services du Ministere de la Cooperation, Division de la Sante at de l'Action soc1ale, Paris Professeur P. PENE, Directeur de l'United'Enseignement et de Recherche de Madecine et de Sante tropicales, Cliniqua exotique l l'H'pital Michel Levy, Marseille M. Andre NEMD. Conseiller, Mission Permanente de la France aupres de l'Office des Nations Unies a Geneve et des Institutions specialis6es ayant leur Siege en Suisse GERMANY. f'EDERAL REPUBLIC OF Mr G.R. LIPTAU, Counsellor, Ministry for Economic Cooperation, Bonn Dr W.O. ERNERT, Ministerial Counsellor, Ministry for Economic Cooperation, Bonn Dr W. SCHUMACHER, Ministerial Counsellor. Federal Ministry for Youih, Family Affai.rs and Heal th, Borm Mr G. WIRTH, Counsellor (Financial Affairs), Permanent Mission of the Federal Republic of Germany to the United Nations Office and other International Organizations at Geneva INDIA Dr C. GOPALAN, Director-General, Indian Council of Medical Research, New Delhi KENYA Dr J.M. GEKONYO, Senior Deputy Director of Medical Services, Ministry of Health, Nairobi KUWAIT Dr Nouri ALKAZEMI. Director, Planning and Public Health Department, Ministry of Public Health, Kuwait
.
.
•
Wft/1C30/9 pa,8 9
MALAYSIA Dr G.F. DE WITT, Director, Institute for Medical Research, Kuala Lumpur MEXICO Dr Augusto Fujigaki LECHUGA, General Director of Epidemiology and Research on Public Health, Ministry ot Public Health, Mexico MOZAMB IQtlE
Dr J. CABRAL, National Deputy Director for Preventive Medicine, Ministry of Haalth, Maputo NETHERLANDS Professor O.J.M. KRANENDONK. Director, Department of Tropical Hygiene, Royal Tropical Institute, Amsterdam Mr F~P.R.
VAN NOUHUYS. First Secretary, Permanent Mission of the Netherlands to the United Nations Oftice and International Organizations at Geneva
NIGERIA Dr O.J. EKANEM, Consul~ant Malariologist, Federal Ministry ot Health~ Lalos
NORWAY Dr T. GODAL. Radiumhospitalet. Oslo Mr H. H0STMARK, First Secretary, Permanent Mi.sion ot Norway to the Unitad Nation. Oftice and to other International Organizations at Geneva PHILIPPINES Dr Paulo CAMPOS, Chairman, Division ot Medicine, National Re.earoh Council ottha Philippine., Manila SUDAN
..
Dr Es Sayed Daoud Hassan DAOUD, Director-General, Laboratories and Medical Research, Khartoum SWEDEN Mr Erik CORNELL. Minister, Permanent Mission of Sweden to the United Nations Office and other International Organizations at Geneva Mr Bo STENSON, Head ot Section, Population and Health Division, ment Authority (SIDA), Stockholm Professor G~ran
Internati~nal
DevelOp-
STERKY, Swedish Agency for Reaaarch Cooperation (S.AR:BC), StockholJa
SWITZERLAND Dr C. FLEURY, Service t6d'ral de l'Hygi~ne
publique, Berne pr~s
M. M. JEANRENAUD, Mission permanente de la Suisse nationales a Geneve
les Organisations inter-
WPR/aC30/9 page 10
Dr J. STR$ULI, Direction de 18 Coop'ration au D'veloppement et de I' Aide humanitair., Derne Dr A. DE GRE MONT , Insti tut tropical, Bile THAILAND 'Professor Yongyoot SUJJAVANICH, Minister of Public Health, Ministry of Public Health. Bangkok TURKEY Dr Necati DEDEOGLU, Department of Epidemiology, School of Public Health. Ankara USSR Dr D.A. ORLOV, CounseuC;;r, Fermanent Mission of the Union of Soviet Socialist Republics to the United Nations Office and other International Organizations at Geneva UN lTED KINGDOM
..
Dr J.L. KILGOUR, Chief Medical Adviser, Ministry of OVerseas Development, London Miss .J.M. DIMOND. Principal. Science, Technology and Medioal Department, Ministry of Overseas Development, London Dr Sheila M. HOWARTH, Principal Medical Officer, Medical Re.earch Council. London UN ITED
STATES OF AMERICA for International Development, Washington
Ms Marjorie S. BELCHER, Deputy Assistant Administrator for Development Support. Agency
Mr James F. THOMSON, Office of Health, Development Support Bureau. Agency for International Development, Washington Mr G.J. KLEIN, Attach', United States Mission to the United Nations Office and other International Organizations at Geneva Mr James E. HILL, Attach' for Development Assistance, United States Mission to the United Nations Office and other International Organizations at Geneva Dr Robert FORTUlNE, International Health Attach', United States Mission to the United Nations Office and other International Organizations at Geneva ZAMBIA Dr S.H. SIWALE, Assistant Director of Medical Services, Planning and Developant, Ministry of Health, Lusaka INTERNATIONAL DEVELOPMENT RESEARCH CENTRE Dr J. GILL. Director, Health Sciences Division, International Development Research Centre, Ottawa JAPAN SHIPBUILDING. INQQS'J.'RY FOuNDATION Professor K. KllKUNI, Managing Director, Sasakawa Memorial Health Foundation, Tokyo
..
WPll/llC30/9 page 11/12
THE WELLCOME TRUST Dr P.O. WILLIAMS, Director, The Wellcome Trust, London UNITED NAT.IONS DEVELOPMENT PROGRAMME Mr William T. MASHLER, Senior Director, Division for Global and Interregional Projects, UNDp, New York Mr W.A.C. MATHIESON, Special Consultant to UNDP, London WORLD BANK Dr James A. LEE, Director, Office of Environmental and Health Affairs, World Bank, Washington Mr George DELAUME, Legal Policy Adviser, World Bank, Washington WORLD HEALTH ORGANIZATION Dr S. FLACHE, SpeCial Programme Coordinator, Assistant Director-General Dr A.O. LUCAS, Director, Special Programme for Research and Training in Tropical Diseases
WPB./aC30/9 page 13
Annex 2
SCIENTIFIC AND TECHNICAL SUMMARY FOR
THE MEMORANDUM OF UNDERSTANDING ON THE ADMINISTRATIVE AND TECHNICAL STRUCTURES
1. Despite the remarkable advances in medical science over recent decades, parasitic diseases still affect or threaten more thaR a thousand million ~ople in the tropical countries, taking heavy t61l in human lives and gravely impeding eeonanic development. Furthermore, rather than coming under control, in many regions some of, these diseases are increasing in both prevalence and severity. 2. This disease bw-den of the tropics is borne by the very people least equipped to control disease - the populations of the developing countries. Not only is development impeded by disease, but some of the development projects, such as manmade lakes and irrigation schemes designed to improve conditions, have in fact altered the ecology and aggravated major public health problems such as malaria and schistosomiasis. 3. In addition, technical problems have significantly reduced the effectiveness of some disease control programmes. A prime example is the increasing resistance of anopheline mosquitos to chemical control, the mainstay of the majority of malaria control programmes. In some areas, such .insecticide resistance in the vector is combined with chloroquine-resistant strains of the malaria paraSite in man, further increasing the severity of the problem. In the case of filarial infections, especially in onchocerciasis, cOJIDDonly called river blindness, there is still no effective and safe drug which can be relied upon to kill the adult worms in man. No vaccine is available for any of the parasitic infections and no new effective, cheap and safe drugs for the widespread treatment of the diseases have become available in the past three decades. 4. To stimulate and coordinate goal-oriented research leading to the development and application of new and improved tools for control of these diseases, the Special Programme for Research and Training in Tropical Diseases has been planned and initiated by the World Health Organization (WHO) with the assistance and co-sponsorship of the United Nations Development Programme (UNDP) and the World Rank (the Bank). This Programme's two principal objectives can be summarized as: research and development for better tools to control tropical diseases, and training and strengthening of institutions to increase the research capability of tropical countries. 5. Criteria for selection of the diseases - malaria, schistosomiasis, filariasis, trypanosomiasis (both African sleeping sickness and the American form called Chagas' disease), leishmaniasis and leprosy - included: th~
impact of the disease as a public health problem;
the absence of satisfactory methods for control of the disease in prevail.ing circumstances of the tropical countries; the presence of research opportunities leading to improved control methods. Since several major problems requiring research apply to most or all of the six
WPR/llC30/9 ;page 14 !
diseases, the Special Programme includes components on epidemiology and operational research, vector control, socia-economic and biomedical research • 6. Each component of the Special Programme is developed under the guidance and with the participation of multidisciplinary groups of scientists organized into a number of Scientific Working Groups, each with clearly defined research goals. 7. Intimately related to this search for new tools is the equally important and interdependent objective: the development of manpOwer and the strengthening of researdh institutions 'in the· endemic countries of the tropics. 8. To these ends, institution strengthening activities focus upon the creation Of a network of collaborating centres in tropical countries. These centres will· become focal points for strengthening the research capabilities of the affected countries and will also be the sites for training activities. 9. The Special Programme is concerned to ensure that the full spectrum of technologists and scientists is trained to carry out the required research in accordance with the decisions and needs of the countries involved. Thus, while the Special Programme is especially concerned with training leaders in research, it is not neglecting the training of supporting workers in the laboratory, the clinic and the field. 10. The Special Programme must be looked upon as a long-term effort of twenty years or more. It is hoped, however, that within the next five years some of the new tools will be ready for extensive trials within the national health services of those countries needing them.
.
-
•